Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2014-10-07 Earnings Release
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
Press Release: 4SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian NSCLC patients and starts randomised Phase II part
Earnings Release Classification · 99% confidence The document is titled 'Press Release' and announces the completion of Phase I and initiation of Phase II of a clinical study by 4SC's partner Yakult Honsha regarding the drug resminostat. It contains key updates, scientific details, and forward-looking statements typical of a corporate announcement regarding clinical trial progress. This type of announcement, which releases key operational/scientific milestones outside of mandated periodic financial reports (like 10-K or IR), is best classified as an Earnings Release (ER) if it contains financial highlights, or more generally, a Regulatory Filing (RNS) if it's a general corporate update. Since this is a specific operational update about a clinical trial milestone, and not a formal earnings report, it fits best under the general 'Regulatory Filings' (RNS) category as a corporate news release, or potentially an 'Earnings Release' (ER) if the context implies it's tied to a reporting period, but RNS is the safer general corporate news category for non-financial specific updates. Given the structure (Press Release, date, key operational news), RNS is the most appropriate fallback for significant corporate news that isn't a standard financial report or management change. Q3 2014
2014-10-07 English
Press Release: 4SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Press Release" and announces a corporate update regarding the completion of a Phase I clinical study and the start of a Phase II study by a partner company (Yakult Honsha) concerning 4SC's compound, resminostat. It contains standard press release formatting, contact information, and boilerplate legal disclaimers typical of corporate news disseminated via services like DGAP. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a specific corporate announcement about clinical trial progress, it fits best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate news item, although it is more specific than a generic RNS. Given the options, and since it is a news announcement rather than a detailed financial report, RNS serves as the most appropriate general category for non-standardized corporate news releases that aren't covered by other specific codes (like DIV, CAP, or ER). However, since it is a press release announcing operational/clinical progress, and not a mandatory regulatory filing like a 10-K or a specific financial event, RNS is the best fit among the provided codes for general corporate news dissemination.
2014-09-23 English
4SC AG issues second tranche of convertible notes with a nominal amount of EUR 500,000 to Yorkville
Capital/Financing Update Classification · 95% confidence The document is explicitly labeled as an 'Ad-hoc' announcement published on September 3, 2014, pursuant to Section 15 of the German Securities Trading Act (WpHG). The content details a specific corporate action: the issuance of the second tranche of convertible notes to Yorkville, including the nominal amount, purpose (funding clinical trials), and terms of conversion. This type of immediate, material corporate event disclosure, especially when labeled 'Ad hoc' and referencing specific securities regulations, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP). Since the primary focus is the immediate announcement of a financing event (issuance of notes), 'CAP' is highly relevant. However, given the structure as a mandatory, immediate regulatory disclosure ('Ad hoc' release pursuant to WpHG) that doesn't fit the more specific categories like 10-K, ER, or DIV, 'RNS' (Regulatory Filings - the general fallback for miscellaneous regulatory announcements) is often the most appropriate catch-all for non-standardized, immediate regulatory disclosures from non-US exchanges, although 'CAP' is also a strong candidate. Given the context of financing activity, I will prioritize CAP, but RNS is the general regulatory bucket. Since this is a specific financing event announcement, CAP is more descriptive than the general RNS fallback.
2014-09-03 English
4SC AG: Dr Thomas Werner and Klaus Kuhn announce resignation from Supervisory Board
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc' announcement dated August 18, 2014, explicitly stating that two members, Dr Thomas Werner and Klaus Kühn, are resigning from the Supervisory Board of 4SC AG. This content directly relates to changes in the company's board of directors or senior management. According to the definitions, this aligns perfectly with the 'Board/Management Information' category.
2014-08-18 English
Q2 Report 2014
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'consolidated half-year financial report' and covers the period ending 30 June 2014. It contains comprehensive financial data, including key figures, revenue, operating profit, and balance sheet items for the 6-month period. It is not a mere announcement or certification, but the full interim report itself, fitting the definition of an Interim / Quarterly Report (IR). H1 2014
2014-08-08 English
Press Release: 4SC Announces Financial Results for the First Half of 2014
Earnings Release Classification · 100% confidence The document is explicitly titled "Press Release: 4SC Announces Financial Results for the First Half of 2014". It contains key financial figures for the first half of 2014 (H1 2014), including revenue, operating loss (EBIT), and earnings per share, comparing them to H1 2013. It also discusses operational events and provides a financial outlook. This content structure—a summary of period results, key figures, management commentary, and segment review for a period shorter than a year—is characteristic of an Interim/Quarterly Report (IR). Although it is presented as a press release announcing the results, the document contains the detailed financial review itself, making it the comprehensive report for the period, not just a brief announcement of publication (RPA). H1 2014
2014-08-07 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.